Analyst: Diagnostics Sector R&D Spending Won't Match FDA Data Demands
This article was originally published in The Gray Sheet
The R&D spend to revenue ratio at emerging and established pure-play diagnostic companies is not sufficient to meet growing FDA requirements for the space, a Morgan Stanley analyst argues.
You may also be interested in...
A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.